JETEMA Valuation

Q: What is the Fair Price of A216080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A216080 (₩17910) is trading below our estimate of [[fair value]] (₩71162.26)

Is A216080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A216080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A216080 (₩17910) is trading below our estimate of fair value (₩71162.26)

Significantly Below Fair Value: A216080 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A216080?

Key metric: As A216080 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A216080. This is calculated by dividing A216080's market cap by their current earnings.
What is A216080's PE Ratio?
PE Ratio	15.8x
Earnings	₩20.23b
Market Cap	₩320.45b

A216080 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.4x
Enterprise Value/EBITDA	30.6x
PEG Ratio	0.4x

Price to Earnings Ratio vs Peers

How does A216080's PE Ratio compare to its peers?

The above table shows the PE ratio for A216080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	36.3x
A003220 Daewon Pharmaceutical	21.3x	44.1%	₩312.5b
A243070 Huons	7.5x	15.3%	₩299.8b
A041960 Komipharm International	24.3x	n/a	₩275.4b
A058820 CMG Pharmaceutical	92.2x	n/a	₩266.8b
A216080 JETEMA	15.8x	35.3%	₩320.5b

Price-To-Earnings vs Peers: A216080 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does A216080's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$49.01m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A216080 is expensive based on its Price-To-Earnings Ratio (15.8x) compared to the KR Pharmaceuticals industry average (15x).

Price to Earnings Ratio vs Fair Ratio

What is A216080's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A216080 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.8x
Fair PE Ratio	23.1x

Price-To-Earnings vs Fair Ratio: A216080 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the estimated Fair Price-To-Earnings Ratio (23.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,270.00

-2.5%

n/a

Medy-Tox

₩856.2b

Operates as a biopharmaceutical company in South Korea.

A086900

₩127,200.00

1.0%

-42.2%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩277,500.00

1.3%

76.0%